00484MAA4
Acorda Therapeutics, Inc.
Could not find a ticker for this position, may be a filing error
A biotechnology company that develops therapies to restore neurological function for people living with multiple sclerosis, Parkinson's disease, and spinal cord injury. Its best-known products are Ampyra, a pill that improves walking in people with MS, and Inbrija, an inhaled treatment for Parkinson's "OFF" episodes. Founded in 1995 by physician Ron Cohen, the company's name plays on the word "accord," reflecting its mission of bringing the body back into balance.
NOTEUnderlying: ACORCUSIP: 00484MAA4HealthcareUS1 derivative reporter
1.75% Senior Unsecured Convertible Note due June 15, 2021
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
